Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Champions Oncology, Inc. (CSBR:NASDAQ), powered by AI.
Champions Oncology, Inc. is currently trading at $6.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Champions Oncology, Inc. on Alpha Lenz.
Champions Oncology, Inc.'s P/E ratio is 18.9.
“Champions Oncology, Inc. trades at a P/E of 18.9 (fair value) with strong ROE of 503.0%.”
Ask for details →Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.
“Champions Oncology, Inc. trades at a P/E of 18.9 (fair value) with strong ROE of 503.0%.”
Ask for details →Champions Oncology, Inc. (ticker: CSBR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 213 employees. Market cap is $89M.
The current price is $6.5 with a P/E ratio of 18.89x and P/B of 23.54x.
ROE is 503.05% and operating margin is 8.51%. Annual revenue is $57M.